| Autor: |
Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX, Lim, Nastasia K-H, Villemagne, Victor L, Soon, Cynthia P W, Laughton, Katrina M, Rowe, Christopher C, McLean, Catriona A, Masters, Colin L, Evin, Genevieve, Li, Qiao-Xin |
| Předmět: |
|
| Zdroj: |
Journal of Alzheimer's Disease; 2011, Vol. 23 Issue 1, p779-786, 8p |
| Abstrakt: |
Pathological changes in the Alzheimer's disease (AD) brain include amyoid-β (Aβ) plaques, and neurofibrillary tangles, as well as neuronal death and synaptic loss. Matrix metalloproteinases MMP-2 and MMP-9 are known to degrade Aβ, and their expressions are increased in the AD brain, in particular in the astrocytes surrounding amyloid plaque. To investigate a possible association between plasma metalloproteinases and AD, we quantified MMP-2 and MMP-9 activities in the plasma of healthy controls (HC, n = 56), cases with mild cognitive impairment (MCI, n = 45), and AD (n = 50). All cases had previously been imaged with Pittsburgh compound B (PiB) and had a Mini-Mental Status Examination (MMSE) assessment. MMP-2 and MMP-9 activity was determined using gelatine-zymography. There was a significant 1.5-fold decrease in MMP-2 activity in the AD group compared to HC (p < 0.001) and a 1.4-fold decrease compared to MCI (p < 0.01). There was no difference in MMP-9 levels between the three groups. A positive correlation was identified between MMP-2 plasma activity and MMSE score (r = 0.16, p < 0.05), but there was no association with PiB. This is the first report of a change in MMP-2 activity in AD plasma and these findings may provide some insight into AD pathogenesis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
